Search results
Children with autism have more gray matter in brain's outer layer than others
UPI· 1 day agoToddlers with autism have cerebral cortexes -- often referred to as "gray matter" -- that are...
After 34 years, Peninsula drug company wins 1st drug approval - San Francisco Business Times
The Business Journals· 1 day agoThe Foster City company's (Nasdaq: GERN) imetelstat — branded as Rytelo — was approved Thursday by the FDA for transfusion-dependent anemia in adult patients with lower risk ...
CARVYKTI® (ciltacabtagene autoleucel) significantly improved progression-free survival and deepened...
Valley City Times Record· 5 days agoJohnson & Johnson announced today results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. Data from the CARTITUDE-4 study supported the recent U.S. FDA approval ...
After lengthy road to FDA approval, Seres sells microbiome pill rights - Boston Business Journal
The Business Journals· 2 days agoSeres Therapeutics Inc. is selling the rights to the microbiome drug it spent more than a decade...
Triplet Notches Survival Win in Heavily Pretreated DLBCL
MedPage Today· 7 days agoBenefit with BV plus lenalidomide-rituximab seen in those who relapsed after CAR-T or transplant
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 3 days agoMitsubishi Tanabe Pharma America to Highlight Expansive ALS Research at the European Network to Cure ALS (ENCALS) 2024 Meeting PR Newswire JERSEY CITY, N.J., June 5, 2024 Data will be presented from eight abstracts spanning preclinical to real-world
Seres sells VOWST assets to Nestlé Health Science By Investing.com
Investing.com· 2 days agoThe deal will see Seres receive an upfront payment along with additional financial considerations,...
HIV/AIDS Fast Facts
KEYT 3 Santa Barbara· 3 days agoCNN Editorial Research (CNN) — Here’s a look at the origins, treatments and global response to HIV and AIDS.FactsHIV stands for human
TECVAYLI® (teclistamab-cqyv) shows sustained deep and durable responses in patients with relapsed or...
Valley City Times Record· 5 days ago"With the longest follow-up of any bispecific antibody, teclistamab demonstrates continued deep and durable responses observed in patients with relapsed or refractory multiple myeloma who have ...
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis...
Benzinga· 5 days agoIn heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety
